New methods to boost the immune system against head and neck cancer
New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer
This study is working on a new vaccine that helps boost the immune system to fight head and neck cancer, especially for those with HPV, by using tiny particles to deliver important signals to your immune cells and looking at how gut health can make this treatment even better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11078271 on NIH RePORTER |
What this research studies
This research focuses on developing innovative tools to enhance the immune response against head and neck squamous cell carcinoma (HNSCC), a challenging cancer with low survival rates. The team is creating a nanoparticle vaccine that delivers specific cancer-related antigens and adjuvants to immune cells, aiming to stimulate strong T-cell responses. Additionally, they are exploring how changes in the gut microbiome can further improve these immune responses. By combining advanced drug delivery techniques with bioengineering, the goal is to create a more effective immunotherapy for patients with HPV-related HNSCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HPV-positive head and neck squamous cell carcinoma who have not responded well to existing immunotherapies.
Not a fit: Patients with non-HPV-related head and neck cancers or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies that significantly improve survival rates for patients with head and neck cancer.
How similar studies have performed: Previous research has shown promise in using nanoparticle vaccines and microbiome modulation to enhance immune responses, indicating a potential for success in this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Moon, James J. — University of Michigan at Ann Arbor
- Study coordinator: Moon, James J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.